


Claims

1. A compound of the general formula (I)



in which:

- 5 G is selected from N and C(R⁵);
L¹ and L² are each independently selected from -NH- and a bond;
R¹ and R² are each independently selected from hydrogen, halogen, C₁₋₃-alkyl, and
C₁₋₃-halogenoalkyl having 1 to 5 halogen atoms, or
R¹ and R², together with the atom to which they are attached, form a
10 C₃₋₆-cycloalkyl;
R³ is selected from C₂₋₆-alkyl, C₃₋₈-cycloalkyl, C₂₋₅-heterocyclyl, and C₁₋₉-heteroaryl,
each optionally substituted with one to five substituents independently selected from
halogen, oxo, -NO₂, -CN, R⁶ and R⁷;
R⁴ is selected from C₃₋₈-cycloalkyl, C₂₋₅-heterocyclyl, C₆₋₁₄-aryl and C₁₋₉-heteroaryl,
15 each optionally substituted with one to five substituents independently selected from
halogen, oxo, -CN, R⁶ and R⁷;
R⁵ is selected from hydrogen, halogen, -CN, C₁₋₄-alkyl, C₂₋₄-alkenyl, C₂₋₄-alkynyl,
C₂₋₅-heterocyclyl, C₁₋₅-heteroaryl, and R¹⁰, wherein the alkyl, alkenyl, alkynyl
moieties are each optionally substituted with one to five substituents independently
20 selected from halogen, -CN, oxo, and R¹⁰, and wherein the heterocyclyl moiety has 3
to 6 ring atoms and the heteroaryl moiety has 5 or 6 ring atoms, and the heterocyclyl
and heteroaryl moieties are each optionally substituted with one to four substituents
independently selected from halogen, -NO₂, -CN, C₁₋₄-alkyl,
C₂₋₄-alkenyl, C₂₋₄-alkynyl, C₁₋₄-halogenoalkyl having 1 to 5 halogen atoms, and R¹⁰;
25 each R⁶ is independently selected from -OR⁸, -N(R⁸)R⁹, -NR⁸C(O)R⁹, -C(O)R⁸, -C(O)OR⁸, -
C(O)N(R⁸)R⁹, -C(O)N(R⁸)OR⁹, -C(O)N(R⁸)S(O)₂R⁹, -N(R⁸)S(O)₂R⁹, -S(O)_nR⁸, and -
S(O)₂N(R⁸)R⁹;
each R⁷ is independently selected from C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₆-cycloalkyl-
(CH₂)_m-, C₆₋₁₄-aryl-(CH₂)_m-, C₂₋₅-heterocyclyl-(CH₂)_m-, and C₁₋₉-heteroaryl-(CH₂)_m-,
30 each optionally substituted with one to five substituents independently selected from

halogen, oxo, -NO₂, -CN, C₁₋₆-alkyl, C₁₋₆-halogenoalkyl having 1 to 5 halogen atoms, and R¹⁰;

each R⁸ and R⁹ is independently selected from hydrogen or from C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₆-cycloalkyl-(CH₂)_m-, C₆₋₁₄-aryl-(CH₂)_m-, C₂₋₅-heterocyclyl-(CH₂)_m- and C₁₋₉-heteroaryl-(CH₂)_m-, each optionally substituted with one to five substituents independently selected from halogen, oxo, -NO₂, -CN, C₁₋₆-alkyl, C₁₋₆-halogenoalkyl having 1 to 5 halogen atoms, and R¹⁰;

each R¹⁰ is independently selected from -OR¹¹, -N(R¹¹)R¹², -N(R¹¹)C(O)R¹², -C(O)R¹¹, -C(O)OR¹¹, -C(O)N(R¹¹)R¹², -C(O)N(R¹¹)OR¹², -C(O)N(R¹¹)S(O)₂R¹², -NR¹¹S(O)₂R¹², -S(O)_nR¹¹, and -S(O)₂N(R¹¹)R¹²;

each R¹¹ and R¹² is independently selected from hydrogen and C₁₋₆-alkyl,;

each n is independently selected from 0, 1 and 2; and


each m is independently selected from 0, 1, 2, 3, and 4;

wherein each of the aforementioned heteroaryl moieties has one to four heteroatoms independently selected from N, O, and S, and each of the aforementioned heterocyclyl moieties is saturated or partially unsaturated and has one or two heteroatoms independently selected from N, O, and S;

and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof, for use in the treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals.

2. The compound for the use according to Claim 1, wherein G is C(R⁵), with R⁵ as defined in claim 1 and/or wherein L¹ is -NH- and/or wherein L² is a bond, and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.

3. The compound for the use according to Claim 1 or 2, according to the general formula (II)




wherein R¹, R², R³, R⁴ and R⁵ independently are as defined in claim 1,


and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.

4. The compound for the use according to Claim 1, 2 or 3, wherein R¹ and R² are both hydrogen, and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.

5. The compound for the use according to Claim 1, 2, 3 or 4, wherein R^3 is 2-amino- C_{3-8} -cycloalk-1-yl, preferably 2-amino-cyclohex-1-yl, optionally substituted with one to four substituents independently selected from halogen, oxo, $-NO_2$, $-CN$, R^6 , and R^7 ,
5 and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.
6. The compound for the use according to Claim 1, 2, 3, 4 or 5, wherein R^4 is a monocyclic C_{2-4} -heteroaryl, preferably pyrazol-4-yl, optionally substituted with one to four substituents independently selected from halogen, oxo, $-CN$, R^6 , and R^7 ,
10 and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.
7. The compound for the use according to Claim 1, 2, 3, 4, 5 or 6, wherein R^4 is substituted with methyl, ethyl, cyclopropyl or C_{1-2} -halogenoalkyl having 1 to 5 halogen atoms, preferably with methyl,
15 and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.
8. The compound for the use according to Claim 1, 2, 3, 4, 5, 6 or 7, wherein R^5 is selected from hydrogen and halogen, preferably from halogen, more preferably from chlorine and fluorine, and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.
20
9. The compound for the use according to Claim 1, 2, 3, 4, 5, 6, 7 or 8, according to the general formula (III) or (IIIa)




(III)




(IIIa),

- 25 and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.
10. The compound for the use according to Claim 1, 2, 3, 4, 5, 6, 7 or 8, according to the general formula (IV) or (IVa)



(IV)



(IVa),

and the diastereomers, enantiomers, metabolites, salts, solvates or solvates of the salts thereof.

5

11. A compound as defined in any one of Claims 1 to 10 for use in the treatment and/or prophylaxis of allergic and/or inflammatory diseases in domestic animals and/or in farm animals.

10

12. Use of a compound as defined in any one of Claims 1 to 10 in the manufacture of a medicament for the treatment and/or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis or endometritis in animals.

15

13. A compound as defined in any one of Claims 1 to 10 for use in the treatment and/or prophylaxis of Atopic Dermatitis and Flea Allergy Dermatitis in dogs or cats, in particular in dogs.

20

14. A composition comprising a compound as defined in any one of Claims 1 to 10 in combination with an inert, non-toxic, pharmaceutically suitable excipient, for use in the treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, preferably for the use in the treatment and/or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals, more preferably for the use in the treatment and/or prophylaxis of Atopic Dermatitis and Flea Allergy Dermatitis in dogs or cats, in particular in dogs.

25

15. The use according to Claim 12, wherein an effective amount of the compound is to be administered to an animal in need thereof.

30

16. Use of a compound as defined in any one of Claims 1 to 10 in the manufacture of a medicament for the treatment and/or prophylaxis of the symptoms of allergic and/or inflammatory diseases in animals, such as in particular of Canine Atopic Dermatitis, wherein the symptoms are one or more selected from the group consisting of itching, excessive scratching, rubbing on the carpet, hair loss (alopecia), greasy or flaky skin with a foul odor, excessive chewing on the paws and areas such as the groin and armpits.
17. Use of a dual SYK and JAK, SYK and IRAK4, or JAK and IRAK4 inhibitor in the manufacture of a medicament for the treatment and/or prevention of allergic and/or inflammatory diseases in animals, preferably for treatment or prevention of canine atopic dermatitis.